In at-risk medical patients, rivaroxaban after discharge did not reduce symptomatic or fatal VTE at 45 days

A. C. Spyropoulos, Andrew Dunn, Henry S. Sacks

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)JC64
JournalAnnals of Internal Medicine
Volume169
Issue number12
DOIs
StatePublished - 18 Dec 2018
Externally publishedYes

Cite this